[{"id":"db96f757-eb81-464e-af66-d76101b2e506","acronym":"","url":"https://clinicaltrials.gov/study/NCT00117975","created_at":"2021-01-18T00:23:45.248Z","updated_at":"2024-07-02T16:37:30.848Z","phase":"Phase 2","brief_title":"Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00117975","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • galiximab (IDEC 114)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/01/2005","start_date":" 06/01/2005","primary_txt":" Primary completion: 06/01/2007","primary_completion_date":" 06/01/2007","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2016-07-06"}]